Viridian Therapeutics, Inc.DE
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc.DE insiders filed 0 open-market purchases and 1 sale; 216 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $3.50B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $348.2K in total
- 1
- 13F holdersQ2 2026, −9 vs. previous quarter
- 216
- 13F valueReported value at the end of Q2 2026
- $2.50B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $70.8M
- +23,359.9% year over year
- Net income, FY2025
- -$342.6M
- No comparable prior period
- Free cash flow, FY2025
- -$276.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $25.8M
- −63.5% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $342.6M (483.6% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 17.0M
- Shares sold short
- Change
- −960.1K
- −5.3% vs. previous
- Days to cover
- 9.07
- At average daily volume
Superinvestors holding VRDN, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding VRDN at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Viridian Therapeutics, Inc.DE insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)8:05 PM ET | Aug 19 | 1 day | Tousignant JenniferChief Legal Officer | SSale | −14.2K | $24.50 | −$348.2K | −100.0%0 after | 2 lots |
| May 13, 2026 (view filing)4:31 PM ET | May 11 | 2 days | Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% Owner | PPurchase | +1.18M | $17.00 | +$20.0M | +30.1%5.09M after | |
| Jan 2, 2026 (view filing) | Dec 31, 2025 | 2 days | Tousignant JenniferChief Legal Officer | SSale | −2.27K | $31.16 | −$70.8K | −100.0%0 after | |
| Oct 27, 2025 (view filing)4:30 PM ET | Oct 23 | 4 days | Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% Owner | PPurchase | +454.5K | $22.00 | +$10.0M | +13.1%3.91M after | |
| Sep 30, 2024 (view filing) | Sep 27 | 3 days | Beetham Thomas W.Chief Operating Officer | PPurchase | +5.00K | $23.41 | +$117.0K | +500.0%6.00K after | |
| Sep 30, 2024 (view filing) | Sep 27 | 3 days | Mahoney Stephen F.President and CEO | PPurchase | +21.4K | $23.33 | +$499.3K | New position21.4K after | |
| Sep 17, 2024 (view filing)9:00 PM ET | Sep 13 | 4 days | Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% Owner | PPurchase | +1.60M | $18.75 | +$30.0M | +86.7%3.45M after | |
| Jan 24, 2024 (view filing)6:44 PM ET | Jan 22 | 2 days | Fairmount Healthcare Fund L.P. and 4 othersDirector, Other: See Remarks | PPurchase | +476.2K | $21.00 | +$10.0M | +34.9%1.84M after | |
| Jun 20, 2023 (view filing) | Jun 15-16 | 5 days | Meisner LaraChief Legal Officer | SSale | −2.30K | $28.02 | −$64.3K | −7.1%30.0K after | 2 lots |
| Jun 6, 2023 (view filing) | Jun 2-6 | 4 days | Meisner LaraChief Legal Officer | SSale | −7.50K | $24.82 | −$186.1K | −20.0%30.0K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 216 holdersThe largest institutional positions in Viridian Therapeutics, Inc.DE at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 16,604,740 | $305.0M | 0.01% | +1,225,363+8.0% | Added |
| BlackRock, Inc. | 8,551,488 | $157.1M | 0.00% | +720,013+9.2% | Added |
| Bellevue Group AG | 6,731,909 | $123.7M | 2.60% | +5,765+0.1% | Added |
| Paradigm Biocapital Advisors LP | 6,723,788 | $123.5M | 2.31% | +3,574,895+113.5% | Added |
| Kynam Capital Management, LP | 6,453,877 | $118.6M | 6.55% | +4,112,225+175.6% | Added |
| State Street Corp | 6,124,976 | $112.5M | 0.00% | +1,452,091+31.1% | Added |
| Price T Rowe Associates Inc | 5,748,410 | $105.6M | 0.01% | +2,542,375+79.3% | Added |
| Fairmount Funds Management LLC | 5,090,928 | $93.5M | 6.18% | +1,176,470+30.1% | Added |
| Vanguard Capital Management LLC | 4,576,860 | $84.1M | 0.00% | +409,659+9.8% | Added |
| Deep Track Capital, LP | 3,592,740 | $66.0M | 0.97% | +2,198,796+157.7% | Added |
Holders of 5% or more of VRDN
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Viridian Therapeutics, Inc.DE.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 13D/A | 14.04%17.2M shares | −1.10 ppfrom 15.14% | Jan 5, 20219 filings | May 13, 2026 | SEC |
| Bellevue Group AG | 13G | 6.60%6.73M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Paradigm Biocapital Advisors LP | 13G/A | 6.10%6.72M shares | +1.00 ppfrom 5.10% | Feb 14, 20227 filings | Aug 14, 2026 | SEC |
| Kynam Capital Management, LP | 13G/A | 5.70%0 shares | +4.16 ppfrom 1.54% | May 15, 20253 filings | Aug 14, 2026 | SEC |
| State Street Corp | 13G | 5.50%6.12M shares | – | Jan 24, 20243 filings | Aug 7, 2026 | SEC |